Sano Chemicals is focused on developing new treatments for drug-resistant infections. For the past several decades, bacteria and fungi have been acquiring resistance to current drugs, requiring the development of new drugs to stay ahead of the evolutionary curve. Antimicrobial resistance (AMR) has led to the increase medical costs and patient populations with unmet medical needs.
Our Pipeline
Occidiofungin: A new antifungal treatment
Occidiofungin is under investigation as a response to increasing prevalence of antifungal resistance. Its unique mechanism of action suggests great potential in the fight against drug resistant fungi. FDA has approved an investigational new drug application (INDA) allowing Phase 1 clinical trials.
Mutacin: A novel antibiotic
Mutacin's spectrum of activity suggests utility against hospital aquired drug-resistant infections of both dermal and systemic nature, including MRSA. In an age of increasing antibiotic resistance, this is of great concern to health and national security agencies.
